Literature DB >> 2910841

Analysis of calcium homeostasis in activated human polymorphonuclear leukocytes. Evidence for two distinct mechanisms for lowering cytosolic calcium.

A Perianin1, R Synderman.   

Abstract

The stimulation of polymorphonuclear leukocytes (PMNs) by chemoattractants triggers a rapid rise in cytosolic free calcium concentration(s) ([Ca2+]i), which quickly returns to base line, suggesting a role for calcium removal in the homeostasis of activated PMNs. To investigate cytosolic calcium homeostasis, PMNs were treated with a fluoroprobe and ionomycin to induce a sustained elevation of [Ca2+]i. The cells were then stimulated, and attenuation of the fluorescence signal was measured as an indication of calcium loss from the cytosol. The formyl peptide chemoattractant N-formyl-methionyl-leucyl-phenylalanine (fMLP), phorbol myristate acetate (PMA), and 1,2-dioctanoyl-sn-glycerol, but not the inactive phorbol ester 4 alpha-phorbol didecanoate, induced a dose-dependent decrease in [Ca2+]i in ionomycin-pretreated cells. However, the decline in [Ca2+]i caused by PMA was sustained and occurred following a lag time, whereas the response to fMLP was immediate, lasted approximately 2 min, and then was followed by a return of [Ca2+]i to its initial level. The restoration of [Ca2+]i required extracellular calcium. Varying the ionomycin concentration allowed studies at different initial [Ca2+]i, which in untreated PMNs was approximately 135 nM. In contrast to fMLP, PMA did not lower calcium at concentrations below 200 nM. The decline in [Ca2+]i induced by fMLP, but not PMA, was blocked by pertussis toxin. In contrast, the decrease in [Ca2+]i caused by PMA and 1,2-dioctanoyl-sn-glycerol, but not fMLP, was inhibited by the protein kinase C antagonists staurosporine, H-7, and sphingosine. These results suggest that formyl peptide chemoattractants transiently stimulate an activity which lowers [Ca2+]i to normal intracellular levels. Activation of this process appears to be independent of protein kinase C. An additional cytosolic calcium lowering activity, dependent on protein kinase C, operates at [Ca2+]i above 200 nM. Thus, activated PMNs can use at least two processes for attentuation of elevated cytosolic calcium levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910841

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  The mechanism of the decrease in cytosolic Ca2+ concentrations induced by angiotensin II in the high K(+)-depolarized rabbit femoral artery.

Authors:  M Ushio-Fukai; H Yamamoto; J Nishimura; K Hirano; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  Staurosporine clamps cytosolic free Ca2+ concentrations of human neutrophils.

Authors:  K Wong; L Kwan-Yeung; J Turkson
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

3.  Receptors linked to polyphosphoinositide hydrolysis stimulate Ca2+ extrusion by a phospholipase C-independent mechanism.

Authors:  L M Broad; T R Cannon; A D Short; C W Taylor
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

4.  Activation of protein kinase C in human neutrophils attenuates agonist-stimulated rises in cytosolic free Ca2+ concentration by inhibiting bivalent-cation influx and intracellular Ca2+ release in addition to stimulating Ca2+ efflux.

Authors:  S A McCarthy; T J Hallam; J E Merritt
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

5.  A protein kinase inhibitor, staurosporine, enhances the expression of phorbol dibutyrate binding sites in human polymorphonuclear leucocytes.

Authors:  C Combadière; E Pedruzzi; J Hakim; A Périanin
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

6.  Protein kinase C activation in human monocytes: regulation of PKC isoforms.

Authors:  Z L Chang; D H Beezhold
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

7.  Altered Ca2+ homeostasis in polymorphonuclear leukocytes from chronic myeloid leukaemia patients.

Authors:  Chetana M Revankar; Suresh H Advani; Nishigandha R Naik
Journal:  Mol Cancer       Date:  2006-11-27       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.